Bristol-Myers Squibb's Taxol

Executive Summary

Three-hour infusion of drug at 135 mg/m or 175 mg/m for refractory ovarian cancer treatment is approved June 22. FDA's Oncology Drugs Advisory Committee recommended the three-hour infusion last fall ("The Pink Sheet" Sept. 27, 1993, T&G-8). Labeling had suggested a 24-hour infusion at 135 mg/m in refractory ovarian cancer. The three-hour schedule "provides physicians experienced in the use of cancer chemotherapeutic agents with an option to administer Taxol in outpatient settings where adequate diagnostic and treatment facilities are readily available," BMS says